Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study

被引:17
作者
Tortelli, R. [1 ]
Copetti, M. [2 ]
Panza, F. [1 ,3 ,4 ,5 ]
Fontana, A. [2 ]
Cortese, R. [3 ]
Capozzo, R. [1 ]
Introna, A. [3 ]
D'Errico, E. [3 ]
Zoccolella, S. [3 ]
Arcuti, S. [1 ]
Seripa, D. [4 ,5 ]
Simone, I. L. [3 ]
Logroscino, G. [1 ,3 ]
机构
[1] Univ Bari Aldo Moro, Unit Neurodegenerat Dis, Dept Clin Res Neurol, Lecce, Italy
[2] IRCCS Casa Sollievo Sofferenza, Unit Biostat, Foggia, Italy
[3] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy
[4] IRCCS Casa Sollievo Sofferenza, Geriatr Unit, Dept Med Sci, Foggia, Italy
[5] IRCCS Casa Sollievo Sofferenza, Lab Gerontol & Geriatr, Dept Med Sci, Foggia, Italy
关键词
additional spreading; amyotrophic lateral sclerosis; generalization; prognosis; survival; DOUBLE-BLIND; ALSFRS-R; PLACEBO; DEXPRAMIPEXOLE; HETEROGENEITY; EPIDEMIOLOGY; DIAGNOSIS; EFFICACY; FOCALITY; SPREAD;
D O I
10.1111/ene.12994
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose: A strong association between time to generalization (TTG), considered as the time of spreading of the clinical signs from spinal or bulbar localization to both, and survival was recently identified in patients with amyotrophic lateral sclerosis (ALS). Thus, TTG may be used as an early to intermediate end-point in survival studies. The aim of the present study was to test TTG as a predictor of survival in ALS. Methods: This was an observational retrospective study of ALS patients from a tertiary referral centre over a 5-year follow-up period. Results: In 212 ALS patients, TTG was associated with time to death/tracheostomy [R 0.62, 95% confidence interval (CI) 0.53-0.70; P < 0.001]. In a time-to-event analysis, longer TTG resulted in lower risk to reach a composite outcome (death or tracheostomy) both in univariate [hazard ratio (HR) 0.98, 95% CI 0.97-0.99] and multivariate Cox analyses (HR 0.98, 95% CI 0.96-0.99). TTG predicted death/tracheostomy at 4 years (C-statistic 0.58; 95% CI 0.53-0.63) and at 5 years (C-statistic 0.58; 95% CI 0.53-0.62). Conclusions: Based on the present results from a large clinical cohort, TTG may be used as a new early to intermediate end-point to describe the ALS natural history. TTG may be potentially useful as a new primary outcome measure for clinical trials.
引用
收藏
页码:1117 / 1125
页数:9
相关论文
共 40 条
[1]   Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients [J].
Abe, Koji ;
Itoyama, Yasuto ;
Sobue, Gen ;
Tsuji, Shoji ;
Aoki, Masashi ;
Doyu, Manabu ;
Hamada, Chikuma ;
Kondo, Kazuoki ;
Yoneoka, Takatomo ;
Akimoto, Makoto ;
Yoshino, Hiide .
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2014, 15 (7-8) :610-617
[2]   EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force [J].
Andersen, Peter M. ;
Abrahams, Sharon ;
Borasio, Gian D. ;
de Carvalho, Mamede ;
Chio, Adriano ;
Van Damme, Philip ;
Hardiman, Orla ;
Kollewe, Katja ;
Morrison, Karen E. ;
Petri, Susanne ;
Pradat, Pierre-Francois ;
Silani, Vincenzo ;
Tomik, Barbara ;
Wasner, Maria ;
Weber, Markus .
EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (03) :360-E24
[3]  
[Anonymous], 2007, BMJ
[4]   Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis [J].
Beghi, Ettore ;
Millul, Andrea ;
Logroscino, Giancarlo ;
Vitelli, Eugenio ;
Micheli, Anna .
AMYOTROPHIC LATERAL SCLEROSIS, 2008, 9 (03) :163-167
[5]   Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS [J].
Beghi, Ettore ;
Pupillo, Elisabetta ;
Bonito, Virginio ;
Buzzi, Paolo ;
Caponnetto, Claudia ;
Chio, Adriano ;
Corbo, Massimo ;
Giannini, Fabio ;
Inghilleri, Maurizio ;
La Bella, Vincenzo ;
Logroscino, Giancarlo ;
Lorusso, Lorenzo ;
Lunetta, Christian ;
Mazzini, Letizia ;
Messina, Paolo ;
Mora, Gabriele ;
Perini, Michele ;
Quadrelli, Maria Lidia ;
Silani, Vincenzo ;
Simone, Isabella L. ;
Tremolizzo, Lucio .
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2013, 14 (5-6) :397-405
[6]   The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials [J].
Beghi, Ettore ;
Chio, Adriano ;
Couratier, Philippe ;
Esteban, Jesus ;
Hardiman, Orla ;
Logroscino, Giancarlo ;
Millul, Andrea ;
Mitchell, Douglas ;
Preux, Pierre-Marie ;
Pupillo, Elisabetta ;
Stevic, Zorica ;
Swingler, Robert ;
Traynor, Bryan J. ;
Van den Berg, Leonard H. ;
Veldink, Jan H. ;
Zoccolella, Stefano .
AMYOTROPHIC LATERAL SCLEROSIS, 2011, 12 (01) :1-10
[7]   The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials [J].
Berry, James D. ;
Miller, Robert ;
Moore, Dan H. ;
Cudkowicz, Merit E. ;
Van den Berg, Leonard H. ;
Kerr, Douglas A. ;
Dong, Yingwen ;
Ingersoll, Evan W. ;
Archibald, Donald .
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2013, 14 (03) :162-168
[9]   The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function [J].
Cedarbaum, JM ;
Stambler, N ;
Malta, E ;
Fuller, C ;
Hilt, D ;
Thurmond, B ;
Nakanishi, A .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 169 (1-2) :13-21
[10]   Early symptom progression rate is related to ALS outcome -: A prospective population-based study [J].
Chiò, A ;
Mora, G ;
Leone, M ;
Mazzini, L ;
Cocito, D ;
Giordana, MT ;
Bottacchi, E ;
Mutani, R .
NEUROLOGY, 2002, 59 (01) :99-103